文献速递重症综合管理与镇静镇痛

重症患者早期康复安全性的德尔菲研究:不良事件定义与血管活性药患者风险评估工具

Assessing the safety of physical rehabilitation in critically ill patients: a Delphi study.
PubMed 文献 · Crit Care · 2024-04-30
一句话结论德尔菲共识定义了54项康复不良事件和50项血管活性药患者康复前须评估的危险因素,为统一安全测量和临床风险评估提供工具。

该研究采用三阶段德尔菲法,由来自五大洲10个国家的24名多专业ICU临床医生和临床研究者参与,并纳入5名既往ICU患者和1名家属参与不良事件定义共识。第一轮开放征集,第二轮采用五点李克特量表评分并以70%共识阈值为标准,第三轮对未达共识条目在匿名反馈下重新评分。结果54项不良事件和50项血管活性药患者康复前须评估的危险因素达到共识,分别形成不良事件工具和风险评估工具,德尔菲过程应答率为97%。作者认为不良事件工具可用于康复研究统一安全测量,风险评估工具可用于指导血管活性药患者启动康复时的临床风险评估。

要点

  • 德尔菲共识形成54项不良事件,构成不良事件工具,用于康复研究统一安全测量。
  • 德尔菲共识形成50项血管活性药患者康复前须评估的危险因素,构成风险评估工具。
  • 共识采用70%同意阈值、五点李克特量表,德尔菲过程应答率97%。
  • 参与专家为10个国家24名多专业ICU临床医生和临床研究者,平均ICU经验18年(标准差8),61%有ICU康复相关发表。
  • 5名既往ICU患者和1名家属参与不良事件定义共识。

适用人群与场景

  • 一般ICU队列的不良事件定义适用于重症患者身体康复研究。
  • 风险评估工具针对接受血管活性药物治疗、拟开始身体康复的重症患者。

诊断标准与关键阈值

  • 共识阈值:第二轮采用五点李克特量表评分,70%同意为达成共识。
  • 第三轮对未达共识的建议在匿名反馈第二轮评分后重新评分。

研究设计与关键结果

  • 三阶段德尔菲研究,24名来自10个国家五大洲的多专业ICU临床医生和临床研究者参与,平均ICU经验18年(标准差8),61%有ICU康复相关发表。
  • 不良事件定义共识纳入5名既往ICU患者和1名患者家属。
  • 德尔菲过程应答率97%。
  • 54项不良事件达到共识,据此创建不良事件工具。
  • 50项接受血管活性药物患者康复前须评估的危险因素达到共识,据此创建第二项工具。

证据类型、等级与局限

  • 证据类型:国际多专业德尔菲共识研究。
  • 试验注册:研究方案回顾性注册于https://www.researchregistry.com/(researchregistry2991)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为不良事件工具可用于身体康复研究,以确保安全性的统一测量。
  • 作者认为风险评估工具可用于临床实践,在接受血管活性药物治疗的患者中评估何时开始康复的风险。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Physical rehabilitation of critically ill patients is implemented to improve physical outcomes from an intensive care stay. However, before rehabilitation is implemented, a risk assessment is essential, based on robust safety data. To develop this information, a uniform definition of relevant adverse events is required. The assessment of cardiovascular stability is particularly relevant before physical activity as there is uncertainty over when it is safe to start rehabilitation with patients receiving vasoactive drugs.

METHODS: A three-stage Delphi study was carried out to (a) define adverse events for a general ICU cohort, and (b) to define which risks should be assessed before physical rehabilitation of patients receiving vasoactive drugs. An international group of intensive care clinicians and clinician researchers took part. Former ICU patients and their family members/carers were involved in generating consensus for the definition of adverse events. Round one was an open round where participants gave their suggestions of what to include. In round two, participants rated their agreements with these suggestions using a five-point Likert scale; a 70% consensus agreement threshold was used. Round three was used to re-rate suggestions that had not reached consensus, whilst viewing anonymous feedback of participant ratings from round two.

RESULTS: Twenty-four multi-professional ICU clinicians and clinician researchers from 10 countries across five continents were recruited. Average duration of ICU experience was 18 years (standard deviation 8) and 61% had publications related to ICU rehabilitation. For the adverse event definition, five former ICU patients and one patient relative were recruited. The Delphi process had a 97% response rate. Firstly, 54 adverse events reached consensus; an adverse event tool was created and informed by these events. Secondly, 50 risk factors requiring assessment before physical rehabilitation of patients receiving vasoactive drugs reached consensus. A second tool was created, informed by these suggestions.

CONCLUSIONS: The adverse event tool can be used in studies of physical rehabilitation to ensure uniform measurement of safety. The risk assessment tool can be used to inform clinical practise when risk assessing when to start rehabilitation with patients receiving vasoactive drugs. Trial registration This study protocol was retrospectively registered on https://www.researchregistry.com/ (researchregistry2991).

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Woodbridge HR, McCarthy CJ, Jones M, et al. Assessing the safety of physical rehabilitation in critically ill patients: a Delphi study. Crit Care. 2024. PMID: 38689372. doi:10.1186/s13054-024-04919-x

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。